John Mascarenhas, MD
Icahn School of Medicine at Mount Sinai · MOUNT SINAI HOSPITAL
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name John Mascarenhas, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:17 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07872709 · Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative NeoplasmsJohn Mascarenhas · not yet recruiting · Myelofibrosis, MPN - Accelerated or Blast Phase, Chric Phase MPN · study director
- Ph1/Ph2NCT07734077 · Revumenib in Patients With MyelofibrosisJohn Mascarenhas · not yet recruiting · Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis · study chair
- Ph2NCT07447817 · Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With CytopeniasJohn Mascarenhas · recruiting · Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis · study chair
- Ph1NCT07320235 · Imetelstat Combinations in Relapsed AMLDouglas Tremblay · recruiting · Relapsed Acute Myeloid Leukemia · study chair
- Ph2NCT05467800 · Study of Canakinumab in Patients With MyelofibrosisJohn Mascarenhas · active not recruiting · Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, ET-MF · study chair
- Ph2NCT04281498 · Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 MutationJohn Mascarenhas · completed · Accelerated/Blast-phase Myeloproliferative Neoplasm, Chronic-phase Myelofibrosis, IDH2 Mutation · study chair
- Ph1NCT03895112 · MPN-RC 118 AVID200 in MyelofibrosisJohn Mascarenhas · completed · Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis · study chair
- Ph2NCT03065400 · PD-1 Inhibition in Advanced Myeloproliferative NeoplasmsJohn Mascarenhas · completed · Chronic Phase Myelofibrosis, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis · study chair
- Ph1NCT02407080 · Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential ThrombocythemiaJohn Mascarenhas · completed · Polycythemia Vera, Essential Thrombocythemia · study chair
- Ph1/Ph2NCT02076191 · Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AMLJohn Mascarenhas · completed · Myeloproliferative Neoplasms · study chair
- Ph2NCT01790295 · Ruxolitinib Prior to Transplant in Patients With MyelofibrosisJohn Mascarenhas · terminated · Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis · principal investigator
- Ph1/Ph2NCT01693601 · Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)John Mascarenhas · completed · Myelofibrosis · principal investigator
- Ph1NCT01291784 · Anti-TGF-beta Therapy in Patients With MyelofibrosisJohn Mascarenhas · terminated · Myelofibrosis, Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase · principal investigator
- Ph3NCT01259856 · Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)Ronald Hoffman · completed · High Risk Polycythemia Vera, High Risk Essential Thrombocythemia · study chair
- Ph2NCT01259817 · Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)Ronald Hoffman · completed · High Risk Polycythemia Vera, High Risk Essential Thrombocythemia · principal investigator
- N/ANCT00665067 · Correlative Biomarker Study in Patients With Myeloproliferative DisordersIcahn School of Medicine at Mount Sinai · completed · Myeloproliferative Disease, Myelofibrosis, Idiopathic Myelofibrosis · principal investigator
- Ph2NCT00572897 · Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for MyelofibrosisJohn Mascarenhas · completed · Myelofibrosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 9 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Project 3: Development of Strategies to Deplete Myelofibrosis Stem CellsP01CA108671 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ronald Hoffman · fiscal years 2006 to 2026
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.